Eli Lilly’s stock dips as Alzheimer’s drug delayed by surprise FDA panel meeting

The FDA is seeking to further understand topics related to evaluating the safety and efficacy of the drug, including results in patients who have taken it and the efficacy implications of the trial design.

Previous post Cloud software provider Astera Labs to offer 17.8 million shares in planned IPO priced at $27 to $30 each
Next post This isn’t a bull market — it’s a ‘duck’ market. Here’s why.